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Abstract
Background: Foot-and-Mouth Disease (FMD) causes significant economic losses in Turkish livestock.
We have analysed the genetic diversity of the 1D sequences, encoding the hypervariable surface protein VP1, of Turkish
isolates of serotype A and O collected from 1998 to 2004 in order to obtain epidemiological and immunological
information.
Results: The 1D coding region of 33 serotype O and 20 serotype A isolates, obtained from outbreaks of FMD between
1998 and 2004, was sequenced.
For serotype A, we confirmed the occurrence of the two subtypes IRN99 and IRN96. These subtypes are most divergent
within the region encoding the immuno-dominant GH-loop. Also a close relationship to Foot-and-Mouth Disease virus
(FMDV) serotype A isolates obtained from outbreaks in Iraq and Iran were detected and a clustering of isolates collected
during the same period of time were found.
The analysis of the deduced amino-acid sequences of these subtypes revealed evidence of positive selection in one site
and one deletion, both within the GH-loop region. By inferring the ancestral history of the positively selected codon,
two potential precursors were found. Furthermore, the structural alignment of IRN99 and IRN96 revealed differences
between the tertiary structures of these subtypes.
The similarity plot of the serotype O isolates suggested a more homogeneous group than the serotype A isolates.
However, phylogenetic analysis revealed two major groups, each further divided in subgroups, of which some only
consisted of Turkish isolates.
Positively selected sites and structural differences of the Turkish isolates analysed, were not found.
Conclusion: The sequence and structural analysis of the IRN99 strains is indicative of positive selection suggesting an
immunological advantage compared to IRN96. However, results of antigenic comparison reported elsewhere do not
substantiate such a conclusion. There is evidence that IRN99 was introduced to Turkey, in all probability from Iran.
Since, a member of the IRN96 lineage was included as a component of the FMDV vaccine produced since 2000, the
outbreaks caused by IRN96 strains in 2004 could be due to incomplete vaccine coverage.
The Turkish type O strains, all with a VP1 structure similar to the O1/Manisa/69 vaccine, appear in several sublineages. 
Whether these sublineages reflect multiple samplings from a limited number of outbreaks, or if they reflect cross-
boundary introductions is not clear.
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Background
Foot-and-Mouth Disease (FMD) is an acute, highly com-
municable and economically important disease caused by
Foot-and-Mouth Disease virus (FMDV). Animals that can
be affected include cattle, swine, sheep, goats, wild pigs,
wild ruminants and buffaloes [1]. FMDV is a positive
sense single-stranded RNA virus (genus Aphthovirus, fam-
ily Picornaviridae) occurring in seven serotypes, O, A, Asia
1, C, SAT 1, SAT 2 and SAT 3, each with a wide spectrum
of antigenic and epidemiological different subtypes. The
wide diversity is considered a consequence of the high
mutation rate and quasi-species dynamic [2].
FMD has been one of the most important diseases causing
significant economic losses in the Turkish livestock sector.
Together with production losses, export restrictions on
several agricultural products cause additional losses to the
Turkish economy [3].
Turkey is of special interest for the European countries,
because it is the natural connection to Asia, where FMD is
enzootic and thus serves as buffer zone against FMD [3].
The two prevalent serotypes in Turkey are A and O [4], and
especially the pandemic FMDV serotype O is a major
threat to Europe, because it is the most aggressive serotype
[5]. However, this type O is still covered by the O1/Man-
isa/69 vaccine [4].
Serotype A displays a great antigenic diversity of subtypes
and there is also often no cross-protection between them
[5]. Since 1999 two subtypes of serotype A have been cir-
culating in Turkey, designated by the World reference Lab-
oratory IAH Pirbright as IRN96 and IRN99 [6].
Turkey practices vaccination against FMD, using a self pro-
duced trivalent vaccine consisting of O1/Manisa/69, Asia1
and since September 2000 a member of the IRN96 lineage
as a replacement for A22, previously included [personal
communication].
Due to the introduction of a twice-yearly national vaccina-
tion campaign in 1996, the number of FMD outbreaks has
decreased significantly, but not homogeneously over the
whole country, which may be explained by vaccine failure
or incomplete vaccine coverage [7].
A common and major epitope of FMDV is located within
the surface protein VP1, containing the immuno-domi-
nant GH-loop and the RGD-integrin binding motif, essen-
tial for cell attachment [8]. Changes in this protein may
cause vaccine failure and changes in host specificity [9].
We describe the genetic diversity of the 1D nucleotide
sequence which encodes for the VP1 protein, in isolates
obtained from outbreaks in Turkish cattle herds between
1998 and 2004 and analyse the data with regard to poten-
tial epidemiological information and to establish possibly
whether FMD outbreaks are caused by viruses persistently
circulating and evolving in Turkey or by strains intro-
duced to Turkey.
Results
Phylogenetic inference
The 1D nucleotide sequence similarity scan (Figure 1) of
the Turkish isolates of the present study reveals two well
separated groups for serotype A. The two groups are most
similar at position 90 nt with 8% divergence given a win-
dows size of 20 nt and most divergent at position 490
with 31% divergence. The latter region encodes the
immuno-dominant GH-loop. The diversity within each of
the two serotype A groups is low within a range of 2–4%.
Serotype O, with O1/Manisa/69 as reference sequence,
displays one homogeneous group, with a diversity in the
range 9%.
The Bayesian tree, based on the 1D nucleotide sequence of
serotype A isolates shown in Figure 2 reveals three clusters
in Turkey, related to A22, IRN96 and IRN99. The most
recent isolate of the A22 cluster, for which sequence infor-
mation is available was collected in Iraq in 1995. The A22
cluster is distinctly separated from the IRN99 and IRN96
lineages as supported by a clade credibility value of 1.0
and the IRN96 and IRN99 clusters are separated as sup-
ported by a clade credibility value of 0.97.
The IRN96 cluster is further subdivided into two temporal
divergent groups, I and II. The isolates of group I all orig-
inate from outbreaks in 1998, it was two years before this
lineage was included in the Turkish FMD vaccine.
The IRN99 related viruses display a single, not further sub-
divided, phylogenetic structure; with the oldest isolate
DQ296550 Igdir/06.99, obtained from an outbreak in
June 1999 in the province Igdir, close to the Iranian bor-
der. Another member of IRN99 lineage is the isolate A/
IRN/22/99# (sequence information kindly provided from
IAH Pirbright) obtained from an outbreak in Iran in 1999.
The inferred phylogeny of serotype O isolates (Figure 3),
with the vaccine lineage as outgroup, displayed two major
clusters A and B, supported by a clade credibility value of
1.0 (Figure 3).
Cluster A is split into the two groups I and II. Group I con-
sists of sequences derived from FMD outbreaks in Paki-
stan and Iran in addition to a single outbreak in January/
February 2004 in the Mersin region of Turkey. The differ-
ential success, expressed as correlation to the number ofBMC Veterinary Research 2006, 2:35 http://www.biomedcentral.com/1746-6148/2/35
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Similarity plot of the 1D nucleotide sequence from the Turkish serotypes O (upper panel) and A (lower panel) obtained in this  study Figure 1
Similarity plot of the 1D nucleotide sequence from the Turkish serotypes O (upper panel) and A (lower panel) 
obtained in this study. Each coloured line indicates a single FMDV nucleotide sequence.BMC Veterinary Research 2006, 2:35 http://www.biomedcentral.com/1746-6148/2/35
Page 4 of 13
(page number not for citation purposes)
Bayesian phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype A isolates (black) and related pub- lished sequences (grey) Figure 2
Bayesian phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype A isolates (black) and 
related published sequences (grey). Numbers on the nodes indicate clade credibility values. Turkey related lineages are 
indicated by names given from the FMD World Reference Laboratory. The vaccine lineage (since 2000) IRN 96 is subdivided 
into two parts, linked to the year of collection. The first occurring isolate, within the IRN 99 cluster is indicated by an asterisk. 
Formats of sequence name: accession number-country/province-year/month, year of collection. Sequences ending with a '#' 
are kindly provided by IAH Pirbright.
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Bayesian phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype O isolates (black) and related pub- lished sequences (grey) Figure 3
Bayesian phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype O isolates (black) and 
related published sequences (grey). The vaccine strain O1 Manisa is used as outgroup. Numbers on the nodes indicate 
clade credibility values. Formats of sequence name: accession number-country/province-year/month, year of collection.
0.1
AJ251477 O1 Manisa Turkey 1969
DQ165055 Iran 2004
DQ164896 Iran 2001
0.52
DQ165049 Iran 2003
DQ165051 Iran 2003
DQ165050 Iran 2003
DQ165056 Iran 2004
DQ164898 Iran 2003
DQ296502 Mersin/01.04
DQ296503 Mersin/02.04
DQ296501 Mersin/02.04 0.35
1.00
0.40
0.74
0.29
0.76
1.00
0.99
DQ165062 Pakistan 2002
DQ165063 Pakistan 2002
DQ165064 Pakistan 2002 0.34
1.00
0.56
DQ165065 Pakistan 2003
DQ164943 Pakistan 2003 1.00
1.00
DQ296505 Sivas/02.01
DQ296504 Igdir/08.98
1.00
0.99
DQ296516 Ankara/12.99
DQ296517 Kirsehir/06.01
DQ296500 Tokat/09.03
DQ296499 Erzincan/10.03
1.00
DQ296523 Ankara/10.02
DQ296518 Ankara/11.02
DQ296519 Sivas/03.02
DQ296520 Kirsehir/03.03 0.99
1.00
0.21
DQ296522 Erzincan/10.02
DQ296521 Malatya/04.02
0.55
0.64
DQ296531 K.Maras/08.03
DQ296530 Amasya/04.04
DQ296498 Afyon/06.04
DQ296527 Afyon/06.04
DQ296525 Afyon/04.04
DQ296526 Kutahya/05.04
DQ296528 Kutahya/05.04
1.00
1.00
1.00
1.00
0.75
0.36
AY312589 South Korea 2004
DQ296515 Konya/10.99
AF506822 Tibet 1999
AY333431 China 2000
AF377945 South Korea 2000
AJ318831 Tibet 1999
AJ294927 Taiwan 1999
AJ539137 Taiwan 1999
AJ539136 Taiwan 1999
AJ539139 South Korea 2000
AY312587 South Korea 2000
AY593824 South Korea 1985
0.32
AB079061 Japan 2000
AJ539140 South Africa
AJ539141 United Kingdom 2001
AJ633821 France 2001
AY593832 United Kingdom 2001
AY593831 United Kingdom 2001
AY593836 United Kingdom 2001
1.00
1.00
1.00
0.93
0.92
AJ539138 Tibet 1999
AJ318832 China 1999
0.88
0.45
DQ296513 Ankara/03.01
DQ296512 K.Maras/02.03
DQ372716 Israel 2005
DQ296511 Erzincan/04.03
DQ164991 Turkey 2003 1.00
0.28
0.35
DQ296510 Eskisehir/09.03
DQ296514 Denizli/11.03
DQ296509 Nigde/08.03
0.34
0.84
DQ296497 Denizili/02.03
DQ296508 Denizili/03.03
DQ296507 Denizil/03.03
DQ296506 Denizili/02.03
0.90
0.83
DQ164919 Lebanon 2003
DQ164902 Israel 2004
DQ165053 Iran 2004
DQ164901 Israel 2004
DQ164900 Israel 2004
1.00
0.99
1.00
1.00
0.99
1.00
1.00
Vaccine  lineage
I
I
II
II
Pan-
asia
A
BBMC Veterinary Research 2006, 2:35 http://www.biomedcentral.com/1746-6148/2/35
Page 6 of 13
(page number not for citation purposes)
substitutions, with regard to the vaccine lineage, is lowest
in the group members obtained from outbreaks in Paki-
stan in 2002 and 2003, intermediate in the Iranian iso-
lates from 2003 and 2004 and most advanced in the
Turkish isolates from 2004.
Group II of cluster A consists of Turkish isolates obtained
from outbreaks in the provinces Sivas in 2001 and Igdir in
1998. The latter province is close to the Iranian border.
The majority of Turkish isolates belong to cluster B, which
can also be subdivided into two groups I and II.
Cluster I of group B was further subdivided into two line-
ages. One group consists of isolates, obtained only from
outbreaks in Turkey and the other of isolates known as the
Panasia lineage. This partition is supported by a clade
credibility value of 0.45. The Turkish lineage displays an
increasing differential success rate, with regard to the vac-
cine strain O1/Manisa/69, starting from the DQ296516
Ankara/12.99 isolate, obtained in the Ankara province in
1999, towards the DQ296528 Kutahya/05.04 isolate,
obtained in the Kutahya province in 2004.
Cluster II of group B consists of viruses obtained from out-
breaks in Turkey, Israel and Lebanon, with the earliest
obtained from an outbreak in the Turkish Ankara region
in 2001.
Positive selection analysis
The examination of the deduced VP1 amino acid
sequences of the serotype O isolates for selective pres-
sures, show no significant (defined as p > 0.5) evidence
for positive selection (data not shown). On the contrary,
residue 151 of serotype A isolates displays significant evi-
dence (p = 0.29) for positive selection (Figure 4 and addi-
tional file 1). Residue 151 is located in the immuno-
dominant GH-loop of the VP1 molecule and therefore
particularly exposed to the immune system of the host.
By investigating the inferred ancestor history of site 151
(additional file 2 and 3), it can be seen that all but two of
the IRN96 isolates, DQ296532 and DQ296533, each col-
lected from the same outbreak, have the common ances-
tor codon 'AGC' (Ser), whereas IRN99 has most likely the
'GGG' (Gly) codon as precursor.
Comparing the translated amino acid sequences of the
whole GH-loop region, located within the residues 140–
160 (Figure 5), reveals that IRN99 isolates consistently
deviates from IRN96 isolates by a deletion at site 153 as
well as in lineage specific conserved amino acids at the
sites: 144, 166, 183, 202 and 203. The integrin-binding
site Arg-Gly-Asp (RGD) [8], was in all serotype A isolates,
but DQ296540, as 'RGDLGAL'-motif present.
Structural analysis
To compare the VP1 protein secondary structure we ana-
lysed the putative hydrophobic and hydrophilic regions
along the length of the VP1 amino acid sequence, using
the Kyte and Doolittle algorithm [10]. This revealed three
different regions for the consensus sequences of the
IRN99 and IRN96 lineages (Figure 6a), as well as two
major disparate regions for representatives of the serotype
O lineages (Figure 7a). The structural alignment of the ter-
tiary structure, based on the consensus sequences of
IRN99 and IRN96 (Figure 6b), shown 75% sequence
identity, revealed appreciable structural differences
between the lineages, within the regions indicated by the
hydrophobicity plot. There is evidence that the IRN96 lin-
eage has two β-sheet structures at the amino acid positions
40–55 and 105–124, where IRN99 has none, as well as a
different helix-structure at position 140–159 (Figure 6b).
From the hydrophobicity plot, DQ296505 Sivas/02.01
seems to represent the most distinct lineage of the Turkish
serotype O isolates (Figure 7a). However, the structural
alignment between DQ296505 Sivas/02.01 and the vac-
cine strain O1/Manisa/69, displays a high similarity of
99% (Figure 7b).
Discussion
The similarity plot (Figure 1), as well as the phylogenetic
analysis of serotype A (Figures 2), confirms the presence
of two independent lineages within our collection of iso-
lates. A member of the IRN96 cluster was not included in
vaccines before September 2000, which means that the
vaccines before that did not provide sufficient protection
against IRN96 strains. However, the IRN96 isolates (Fig-
ure 2, IRN96 II) collected from outbreaks in 2004, and the
clustering of these isolates with the IRN96 isolates from
Iran and Iraq alternatively suggests multiple introductions
from one or both of these countries.
The IRN99 lineage is suggested to be a newly introduced
lineage rather than an escape mutant lineage evolved from
IRN96. This is supported by the lack of evolutionary inter-
mediates between the two clusters, the consistent differ-
ences between isolates of the two clusters and the low
probability of a common ancestor of residue 151 poten-
tially subject to positive selection. In addition that the first
IRN99 isolate reported in Turkey originate from an out-
break in the province of Igdir, close to the Iranian border.
The structural alignment of IRN99 and IRN96 (Figure 6)
revealed significant conformational differences within
this important immuno-dominant protein suggesting an
immunological advantage of IRN 99 strains given that a
member of the IRN96 is used as a vaccine component.
However, antigenic comparisons based on virus neutrali-
sation analysis and epidemiological data previously
reported [12] do not substantiate such a conclusion.BMC Veterinary Research 2006, 2:35 http://www.biomedcentral.com/1746-6148/2/35
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Recalling the fact that structures are more conserved in
evolution than sequences, these observed differences sup-
port the idea of an independently evolved IRN99 lineage.
Recombination events between the two serotype A types
IRN99 and IRN96 within the 1D region were not detected
by the similarity scan. This may indicate that both sero-
types A types are in the phase of high fitness and have
found their particular ecological niche.
In contrast to the serotype A strains, the serotype O iso-
lates included in this study constitute a more homogene-
ous group, as shown by the similarity plot (Figure 1).
The phylogenetic analysis of serotype O isolates demon-
strate the presence of two major subtypes, cluster A and B
(Figure 3), each further subdivided in distinct lineages.
Cluster A I contained isolates from one single outbreak in
the Turkish Mersin province, as well as isolates obtained
from earlier outbreaks in Pakistan and Iran. The temporal
distribution and the differential success of these isolates,
i.e. the branch lengths, suggest that the virus was intro-
duced from Pakistan to Iran and then to Turkey. Cluster A
II, consisting of the Turkish isolates DQ296505 Sivas/
02.01 and DQ296504 Igdir/08.98, is well separated from
A I and represent a sublineage only observed in Turkey.
The same conclusion may be valid for the cluster B I,
which also exclusively comprised Turkish isolates. How-
ever, the intermediate clade credibility value of 0.45 at the
node between cluster B I and the Panasia lineage may
indicate a closer relationship to the pandemic Panasia lin-
Sliding window representing the rate of synonymous and nonsynonymus nucleotide substitutions per site from serotype A  sequences Figure 4
Sliding window representing the rate of synonymous and nonsynonymus nucleotide substitutions per site from 
serotype A sequences. The extent of positive and negative selection on individual codons. The value above and below the 
abscissa, indicates the number of per-site nonsynonymus substitutions (dN) over per-site synonymous ones (dS) in an individual 
codon. The zero value means dN = dS. Site 151 shows evidence for significant positive selection (P < 0.05) based on the 
extended binomial distribution.
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eage than displayed in the phylogenetic tree. An explana-
tion for these purely Turkish sublineages may be that the
virus is circulating in Turkish cattle herds, either through
subclinically infected cattle or by transmission to cattle
from other reservoirs such as sheep and goats.
Cluster B II is clearly separated from the Panasia lineage,
consisting of isolates from newer outbreaks in Turkey,
Israel and Lebanon, indicating the spread of this subline-
age.
Nevertheless, the structural comparison between the field
isolates and the vaccine strain O1/Manisa/69 (Figure 8)
displayed no distinct differences suggesting that the vac-
cine strain, O1/Manissa/69, in current use should provide
full protection. This suggestion is concordant with other
studies [11,12].
Conclusion
In conclusion, this study confirmed the presence of two
major serotype A lineages, namely IRN 99 and IRN96, in
Turkey. There was no evidence that the A22 strain was
present in Turkey during the examined period of time,
however this may be related to the small sample size used
in this study. The sequence and structural analysis of the
IRN99 related viruses revealed potential conformational
differences of the IRN99 VP1 possibly affecting the anti-
genic properties of particular regions. There is evidence
that IRN99 is introduced from outside to Turkey, in all
probability from Iran.
Since, the IRN96 lineage is a component of the FMDV vac-
cine used since 2000, the outbreaks in 2004 occurred
most probably due to incomplete vaccine coverage.
The endemic, slowly evolving Turkish O lineages, with a
predicted VP1 structure similar to the O1 Manisa vaccine,
occurs in several sublineages in Turkey. Some of these
sublineages are most probably introduced from neigh-
bouring countries, whereas others are circulating within
Turkish cattle or are frequently reintroduced to cattle from
persistently infected small ruminants, i.e. sheep and goats,
which share pastures and transport vehicles.
Methods
Virus isolates
Thirty-three serotype O (Accession numbers: DQ296497
– DQ296531) and twenty serotype A (Accession numbers:
DQ296532 – DQ296552) field isolates were collected
from 1998 to 2004 from bovine herds widely distributed
in Turkey. All isolates were epidermal tissue samples rep-
resenting vesicular lesions and had been stored in TRI-
ZOL©-reagent. Province and time (month/year) of
collection are indicated with the accession numbers.
Amino Acid – alignment of the GH-loop (residues 140–160) from both serotype A lineages IRN99 and IRN96 Figure 5
Amino Acid – alignment of the GH-loop (residues 140–160) from both serotype A lineages IRN99 and IRN96. 
Virus isolates are named after the Genbank Accession-number. Complete deletion at site 153 of the IRN99 lineage, as well as 
lineage specific conserved amino acids at the sites: 144, 166, 183, 202 and 203. The potential integrin binding site Arg-Gly-Asp 
(RGD) [8], is in all but DQ296541, as 'RGDLGAL'-motif present.
IRN96
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Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the both serotype A lin- eages IRN99 andIRN96 Figure 6
Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the 
both serotype A lineages IRN99 andIRN96. Significant differences are indicated by coloured bar, where the colour refers 
to the part of the structural model.
IRN99
IRN96
-4
-3
-2
-1
0
1
2
3
3 13 23 33 43 53 63 73 83 93 103 113 113 123 133 143 153 163 173 183 193
position
K
y
t
e
&
D
o
o
l
i
t
t
l
e
h
y
d
r
o
p
h
o
b
i
c
i
t
y
s
c
o
r
e
s
K
y
t
e
&
D
o
o
l
i
t
t
l
e
h
y
d
r
o
p
h
o
b
i
c
i
t
y
s
c
o
r
e
s
IRN99
IRN96
a
bBMC Veterinary Research 2006, 2:35 http://www.biomedcentral.com/1746-6148/2/35
Page 10 of 13
(page number not for citation purposes)
Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the main serotype O  subtypes Figure 7
Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the 
main serotype O subtypes. Significant differences are indicated by coloured bar, where the colour refers to the part of the 
structural model.
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RNA extraction, reverse transcriptase – PCR and cycle 
sequencing
Tissue (100–150 mg) was homogenized in 1 ml RNApro™
Solution (Qbiogene, USA) in a Lysing Matrix D tube
(Qbiogene, Inc., USA) using a FP 120 Fast Prep™ Cell Dis-
ruptor (Qbiogene, USA). Total RNA was extracted using
RNeasy-Mini Kit™ (Qiagen, Germany) according to man-
ufacturer's instructions. cDNA synthesis was done using
Ready-To-Go™ You-Prime First-Strand Beads (GE Health-
care Life Sciences, Sweden), employing the primers
NV27T and random hexamers pdN6.
Five μl of the template cDNA were added to 45 μl of the
PCR reaction mixture containing 0,2 μM primers (see
Table 1), 200 μM each of dATP, dCTP, dGTP and dTTP, 10
mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2 and 1
U of AmpliTaq® Gold DNA polymerase (Applied Biosys-
tems, UK). DNA was amplified with a DNA Thermal
Cycler PE9700 (Perkin Elmer) by a two-step cycling reac-
tion as follows: 95°C for 15 min, and five cycles of 94°C
for 30 sec, 57°C for 2 min and 72°C for 30 sec, and then
35 cycles of 94°C for 30 sec, 61°C for 30 sec and 72°C for
30 sec, followed by a final extension step of 72°C for 10
min.
The resulting PCR product was examined by electrophore-
sis, using a 1,2% agarose gel, containing 0,005% ethidium
bromide, with a separation time of 1,5 hours at 6,5 V/cm.
Amplicons were extracted and purified from agarosegel
with QIAquick Gel Extraction kit (Qiagen, Germany) and
cycle-sequencing was then performed by Agowa GmbH,
Germany.
Multiple alignment
Sequence assembling was performed with ContigExpress
(VectorNTI©-software) and multiple alignment was per-
formed by log-expectation comparison, using the MUS-
CLE (v.3.6) software [13]. For the serotype A alignment
manual editing at codon position 153 was done.
Similarity analysis
Similarity plots were performed using Simplot software
[14] with the following parameters: For serotype A a win-
dows size of 100 bp (step: 20 bp) with gap-stripping and
Jukes-cantor correction was chosen, whereas a window of
200 bp (step:20 bp) with gap-stripping and Kimura (2-
parameter) correction was chosen for serotype O.
Phylogenetic analysis
Models of evolution were determined by hierarchical
Likelihood-Ratio test of 24 substitution models, using the
programs PAUP*(v. 10) [15] and MrModeltest (v. 2.2)
[16].
For serotype A the HKY+G was used and Bayesian analysis
was performed using MrBayes (v3.2) [17] with the follow-
ing settings. The maximum likelihood model employed 2
substitution types ("nst = 2"), with base frequencies set to
fixed values ("statefreqpr = fixed"). Rate variation across
sites was modelled using a gamma distribution (rates =
"gamma"). The Markov chain Monte Carlo search was run
with 4 chains for 500000 generations, with trees begin
sampled every 100 generations (the first 1000 trees were
discarded as "burnin").
For serotype O the GTR+G was used and Bayesian analysis
was performed using MrBayes (v3.2) [17] with the follow-
ing settings. The maximum likelihood model employed 6
substitution types ("nst = 6"), with base frequencies set to
variable values ("statefreqpr = dirichlet(1,1,1,1)"). Rate
variation across sites was modelled using a gamma distri-
bution (rates = "invgamma"). The Markov chain Monte
Carlo search was run with 4 chains for 500000 genera-
tions, with trees begin sampled every 100 generations (the
first 1000 trees were discarded as "burnin").
Table 1: Primers used in this study
Sense/Antisense Designation Sequence (5' to 3') Published by
Sense O-1C244F GCAGCAAAACACATGTCAAACACCTT [26]
Sense O-1C272F TBGCRGGNCTYGCCCAGTACTAC [26]
Sense O-1C283F GCCCAGTACTACACACAGTACAG [26]
Antisense NK61 GACATGTCCTCCTGCATCTG [26]
Sense SV1 GCGCCACACCGCGTGTTGG [27]
Antisense P1 GAAGGGCCCAGGGTTGGACTC [27]
Sense P498¶ AATTACACATGGCAAGGCCGACGG [28]
Antisense P617 rc CCCGAGTGGCTTTGATGG [28]
Sense A1 ACCAATGTACAGGGATGGGT This study
Antisense A2 TTGCACCGTAGTTAAAGGAA This study
Sense B1 CTGAGAGAGCTGCACACTGC This study
Antisense B2 GTACTTGCTCGTCCCGTTGT This studyBMC Veterinary Research 2006, 2:35 http://www.biomedcentral.com/1746-6148/2/35
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Selection pressure analysis
Positively selected sites (Codon-specific analyses of dN/
dS) was identified using the Single Likelihood Ancestor
Counting (SLAC) analysis [18], a modification of the
Suzuki-Gojobori method [19], available at the Datamon-
key web side [18]. For both serotypes, the analysis was
done with the HKY85 substitution model on phylogenetic
trees inferred using the Neighbour-Joining method with a
cut-off p value of 0.5.
Structural analysis
Three-dimensional structure of the VP1 protein was
obtained using comparative protein modelling [20],
employing the CPHmodels 2.0 Server [21] and pairwise
structure comparison was done using the DaliLite work-
bench [22]. Molecule Visualization was done using RAS-
MOL 2.7 software [23].
The structural analysis of the A serotype is based on the
comparison of the translated amino acid consensus
sequences from the IRN96 and IRN99 lineage. Both,
IRN99 consensus and IRN96 consensus sequences, used
the structure of serotype A-1061 (1ZBA:1; Resolution: 2 Å)
[24] as template.
For serotype O viruses the structural analysis was based on
the translated amino acid sequences of DQ296505 Sivas/
02.01 and the vaccine strain O1/Manisa/69. Both used the
structure of strain O-1860 (1FOD:1; Resolution: 2,6 Å)
[25] as template.
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